Abstract
BackgroundAlthough immune checkpoint inhibitor (ICI) approval has changed the treatment landscape of metastatic urothelial carcinoma, approximately 70% of patients succumb to refractory or acquired resistance. Tumor-cell intrinsic upregulation of PPARG...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have